Edition:
United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

19.17USD
3:52pm BST
Change (% chg)

$-0.50 (-2.54%)
Prev Close
$19.67
Open
$19.71
Day's High
$19.89
Day's Low
$18.59
Volume
37,798
Avg. Vol
269,816
52-wk High
$24.30
52-wk Low
$11.12

Select another date:

Wed, May 23 2018

Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge

Shares of Cara Therapeutics surged more than 20 percent on Wednesday after it signed a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd that could give the U.S. drug developer up to $470 million in milestone payments.

BRIEF-Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement

* CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS

BRIEF-Vifor Pharma: VFMCRP And Cara Therapeutics To Develop And Commercialise CR845 Injection For Chronic Kidney Disease-Associated Pruritus

* VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cara Therapeutics Reports Q1 Loss Per Share $0.51

* CARA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Select another date: